179 related articles for article (PubMed ID: 21326122)
1. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
Saga T; Koizumi M; Inubushi M; Yoshikawa K; Tanimoto K; Fukumura T; Miyamoto T; Nakajima M; Yamamoto N; Baba M
Nucl Med Commun; 2011 May; 32(5):348-55. PubMed ID: 21326122
[TBL] [Abstract][Full Text] [Related]
2. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
3. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
5. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
[TBL] [Abstract][Full Text] [Related]
6. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
[TBL] [Abstract][Full Text] [Related]
7. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
[TBL] [Abstract][Full Text] [Related]
9.
Christensen TN; Langer SW; Persson G; Larsen KR; Loft A; Amtoft AG; Berthelsen AK; Johannesen HH; Keller SH; Kjaer A; Fischer BM
J Nucl Med; 2021 May; 62(5):628-635. PubMed ID: 33037090
[TBL] [Abstract][Full Text] [Related]
10. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
11. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
13. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
14. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
15. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
19. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
20. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
